0.4315EUR+7.61%Mkt Cap: 222.06M EURP/E: —Last update: 2026-06-01
Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy developm…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap222.06M EUR
Enterprise Value160.18M EUR
Revenue (TTM)5.81M EUR
Gross Profit5.81M EUR
Net Income (TTM)-29.43M EUR
Revenue/Share0.0190 EUR
Last Price0.4315 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees63
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0012596468
Valuation
P/E (Trailing)—
P/E (Forward)-5.35
PEG—
EV/EBITDA-5.38
EV/Revenue27.55
P/S35.49
P/B2.71
EPS (TTM)-0.10
EPS (Forward)-0.07
52W Range
0.273030% of range0.8080
52W High0.8080 EUR
52W Low0.2730 EUR
Profitability
Gross Margin100.00%
Oper. Margin-399.80%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-66.16%
ROA-50.84%
Growth
Revenue Growth5.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-27.28M EUR
CapEx (TTM)756.00K EUR
FCF Margin-298.79%
FCF Yield-7.82%
Net Debt-46.22M EUR
Net Debt/EBITDA1.55
Balance Sheet
Debt/Equity0.03
Current Ratio4.59
Quick Ratio4.53
Book Value/Sh0.1480 EUR
Cash/Share0.0920 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)1.302 EUR
Target Range1.000 EUR – 2.000 EUR
# Analysts4
Ownership
Shares Out.514.63M
Float300.41M
Insiders34.81%
Institutions36.53%
Technical
SMA 500.4039 (+6.8%)
SMA 2000.3604 (+19.7%)
Beta0.36
S&P 52W Chg27.94%
Avg Vol (30d)1.83M
Avg Vol (10d)1.20M
Technical Indicators
RSI (14)49.9
MACD-0.0018
MACD Signal-0.0014
MACD Hist.-0.0004
BB Upper0.4354 EUR
BB Middle0.4046 EUR
BB Lower0.3737 EUR
BB Width15.23%
ATR (14)0.0283 EUR
Vol Ratio (20d)1.33x